{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:58:39Z","timestamp":1781002719146,"version":"3.54.1"},"reference-count":14,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pacing Clinical Electrophis"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) have been associated with reduced atrial fibrillation (AF) recurrence after catheter ablation in obese and diabetic populations, largely attributed to weight reduction. Whether these agents provide weight\u2010independent antiarrhythmic benefits remains unclear. We evaluated the association between GLP\u20101 RA therapy and long\u2010term clinical outcomes following AF ablation in non\u2010obese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study using the TriNetX U.S. Collaborative Network. Adults (\u226518 years) with body mass index (BMI) \u226429.9\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      who underwent AF ablation between 2010 and 2025 were identified. Patients receiving GLP\u20101 RAs within 6 months of ablation were compared with non\u2010users. Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory variables. Outcomes were assessed at 1 and 3 years following a 3\u2010month blanking period. Primary endpoints included atrial flutter, cardioversion, repeat ablation, and antiarrhythmic drug (AAD) use. Secondary outcomes included heart failure exacerbation, all\u2010cause hospitalization, stroke, and mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 1749 patients were included in each group (mean age 68 years; 38% female). At 1 year, GLP\u20101 RA use was associated with lower cardioversion (hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.40\u20130.91), reduced AAD use (HR 0.68; 95% CI 0.61\u20130.77), decreased heart failure exacerbation (HR 0.53; 95% CI 0.32\u20130.85), and fewer hospitalizations (HR 0.69; 95% CI 0.51\u20130.94). Repeat ablation, stroke, and mortality were similar. At 3 years, reductions in cardioversion, AAD use, and heart failure exacerbation persisted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In non\u2010obese patients undergoing AF ablation, GLP\u20101 RA therapy was associated with reduced arrhythmia\u2010related interventions and heart failure exacerbation, supporting potential weight\u2010independent antiarrhythmic effects. Prospective trials are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/pace.70317","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:16:24Z","timestamp":1781000184000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of GLP\u20101 Receptor Agonist on Atrial Fibrillation Recurrence After Catheter Ablation in Non\u2010Obese Patients"],"prefix":"10.1111","author":[{"given":"Saeed","family":"Abughazaleh","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts\u2010Baystate  Springfield Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-0434","authenticated-orcid":false,"given":"Khalid","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts\u2010Baystate  Springfield Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Al","family":"Nawaiseh","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease University of Connecticut School of Medicine\/Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker","family":"Al\u2010Nabulsi","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons in Irland  Dublin 2 Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colby","family":"Salerno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts\u2010Baystate  Springfield Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshal","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts\u2010Baystate  Springfield Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Chalhoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts\u2010Baystate  Springfield Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"25","key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022","volume":"82","author":"Mensah G. A.","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/2047487317715769","article-title":"Atrial Fibrillation and the Risk for Myocardial Infarction, All\u2010Cause Mortality and Heart Failure: A Systematic Review and Meta\u2010Analysis","volume":"24","author":"Ruddox V.","year":"2017","journal-title":"European Journal of Preventive Cardiology"},{"issue":"7","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jacep.2024.03.006","article-title":"Rhythm Vs Rate Control Strategy for Atrial Fibrillation: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"10","author":"Zafeiropoulos S.","year":"2024","journal-title":"Clinical Electrophysiology"},{"issue":"6","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamacardio.2021.0852","article-title":"Assessment of Catheter Ablation or Antiarrhythmic Drugs for First\u2010Line Therapy of Atrial Fibrillation: A Meta\u2010Analysis of Randomized Clinical Trials","volume":"6","author":"Turagam M. K.","year":"2021","journal-title":"JAMA Cardiology"},{"issue":"1","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar J. A.","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular Effects and Tolerability of GLP\u20101 Receptor Agonists: A Systematic Review and Meta\u2010Analysis of 99,599 Patients","volume":"86","author":"Galli M.","year":"2025","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156463","article-title":"Effect of GLP\u20101 Receptor Agonists and Co\u2010agonists on Atrial Fibrillation Risk in Overweight or Obesity: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"175","author":"Karakasis P.","year":"2025","journal-title":"Metabolism"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti\u2010inflammatory Role of Glucagon\u2010Like Peptide 1 Receptor Agonists and Its Clinical Implications","volume":"15","author":"Alharbi S. H.","year":"2024","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"issue":"1","key":"e_1_2_9_10_1","article-title":"Impact of GLP\u20101 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real\u2010World Data Analysis","volume":"19","author":"Venier S.","year":"2026","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"10","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s12325-024-02959-x","article-title":"Effects of Glucagon\u2010Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta\u2010Analysis","volume":"41","author":"Karakasis P.","year":"2024","journal-title":"Advances in Therapy"},{"issue":"11","key":"e_1_2_9_12_1","article-title":"Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study","volume":"18","author":"Guo J.","year":"2025","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"8","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of Glucagon\u2010Like Peptide\u20101 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation","volume":"10","author":"Satti D. I.","year":"2024","journal-title":"Clinical Electrophysiology"},{"issue":"11","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular Actions of Incretin\u2010Based Therapies","volume":"114","author":"Ussher J. R.","year":"2014","journal-title":"Circulation Research"},{"issue":"8","key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon\u2010Like Peptide\u20101 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice","volume":"8","author":"Bohne L. J.","year":"2023","journal-title":"Basic to Translational Science"}],"container-title":["Pacing and Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pace.70317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pace.70317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pace.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:16:28Z","timestamp":1781000188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pace.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":14,"alternative-id":["10.1111\/pace.70317"],"URL":"https:\/\/doi.org\/10.1111\/pace.70317","archive":["Portico"],"relation":{},"ISSN":["0147-8389","1540-8159"],"issn-type":[{"value":"0147-8389","type":"print"},{"value":"1540-8159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2026-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"pace.70317"}}